Anti-nerve growth factor monoclonal antibodies – Safety
Safety
Published 10 September 2025
All veterinary pharmaceutical agents must provide safety and efficacy data as part of the process of achieving their marketing authorisation, and this information will be included in the summary of product characteristics. However, it is also important to monitor and report adverse events, which includes lack of efficacy, once a product is in use. This information may come from published studies and/or post authorisation pharmacovigilance.
When referring to the frequency of adverse events the definitions of frequency may differ from those in common usage
| Very common | ≥1/10 |
| Common | ≥1/100 to <1/10 |
| Uncommon | ≥1/1,000 to <1/100 |
| Rare | ≥1/10,000 to <1/1,000 |
| Very rare | <1/10,000 |
- Walters, R.R., Boucher, J.F. and De Toni, F. (2021) Pharmacokinetics and immunogenicity of frunevetmab in osteoarthritic cats following intravenous and subcutaneous administration. Frontiers in Veterinary Science, 8, 687448. https://doi.org/10.3389/fvets.2021.687448
- Monteiro, B.P. et al. (2025) Global pharmacovigilance reporting of the first monoclonal antibody for canine osteoarthritis: a case study with bedinvetmab (Librela™). Frontiers in Veterinary Science, 12, 1558222. https://doi.org/10.3389/fvets.2025.1558222
- Farrell, M. et al. (2025) Musculoskeletal adverse events in dogs receiving bedinvetmab (Librela). Frontiers in Veterinary Science, 12, 1581490. https://doi.org/10.3389/fvets.2025.1581490
Claiming CPD for reading inFOCUS articles
Reading and reflecting on articles can count towards your CPD, and we have a template to help you with the process.
Online full-text available to Library members
A range of library membership packages is available and MRCVS vets and RVNs can join the library for a heavily subsidised, annual fee.
Leave a Reply
Want to join the discussion?Feel free to contribute!